With the ultimate goal of preventing half a million teens from abusing medicine within five years, The Partnership at Drugfree.org will launch The Medicine Abuse Project during the week of September 23-29, 2012. The launch week will kick start a multi-year effort to help educate parents, teens and the public about the dangers of medicine abuse and unite parents, educators, health care providers, coaches, government officials, law enforcement officers and other partners to help save lives.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54143-the-partnership-at-drugfree-org-medicine-abuse-project-teen-education
http://www.getthehormonecure.com Dr.
Sara Gottfried refuses to accept the traditional medical thinking that
feeling cranky, asexual, tapped out, and sleep-deprived is just part of
being female and aging, and that prescription medication will fix all
problems. In The Hormone Cure, she combines natural therapies with
rigorous scientific testing to help women feel fully alive, especially
in the years prior to menopause. Using an informative questionnaire to
identify common symptoms of hormonal imbalance such as insomnia, low
sex drive, lack of energy, moodiness, hot flashes, and more; detailing
causes; and offering solutions in non-judgmental and thoughtful
language, Dr. Gottfried provides a novel plan based on solid scientific
research. She believes you don't find a cure at the bottom of a pill
bottle.
Eight out of 10 people will be affected by back pain at some point during their lives, making it the No. 1 cause of disability worldwide and resulting in as much as $200 billion in lost wages and productivity. Many sufferers struggle for years to find relief, but treatment options often only provide short-term relief or, in the case of pain medication, carry serious side effects, including drowsiness, liver damage and potential for addiction. Now, thanks to Hocoma, a leader in the development of robotic and sensor-based medical devices for functional movement therapy, consumers have a new way to improve and sustain low back health in the comfort of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7370551-hocoma-innovative-medical-device-therapeutic-gaming-technology-valedo-low-back-health/
Vioxx Settlement
This is an important announcement for consumers about the prescription drug Vioxx. Vioxx was a drug commonly used to treat pain and inflammation in adults with arthritis.
A settlement was reached with the manufacturer of Vioxx and will provide refunds to anyone who paid for the medication. Consumers are eligible to get $50 or more. Personal injury claims related to this drug are not included in this settlement.
The deadline to file a claim is approaching – claims must be filed by May 6, 2014.
Details are available at http://www.VioxxSettlement.com or by calling 1-866-439-6932.
Nancy Lieberman, basketball hall of famer, coach and mom, has teamed up with Sanofi’s consumer healthcare division Chattem Inc. to introduce a new, more effective player on the over-the-counter (OTC) allergy medication roster, Nasacort Allergy 24HR Nasal Spray. Now available in stores nationwide, Nasacort Allergy 24HR is different than other currently available OTC allergy medications. It puts the “Full ‘Cort Press” on the full range of nasal allergy symptoms for 24 hours with a once daily dose. Nasacort Allergy 24HR is the first and only medicine in its class to be available at full prescription strength without the need for a prescription.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7122351-basketball-hall-of-famer-nancy-lieberman-nasacort-allergy-24hr
Duchesnay USA launched a new online video series today about pregnancy health and morning sickness, which many don’t know is a medical condition called Nausea and Vomiting of Pregnancy (NVP). The series, entitled Navigating Morning Sickness, premiered with three videos about pregnancy nutrition, medication safety and the potential impact of NVP on a pregnant woman’s life. Additional new videos will be released throughout November and December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64373-duchesnay-usa-online-video-series-pregnancy-morning-sickness
TruTag Technologies, Inc., Honolulu-based innovator of an edible security platform to address the trillion dollar global counterfeit problem and the issue of food and medicine safety, has been named a 2014 Technology Pioneer by the World Economic Forum.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63075-trutag-technologies-2014-technology-pioneer-by-world-economic-forum
Se pone en marcha el primer estudio integral a largo plazo que compara diferentes medicaciones para el tratamiento de la diabetes tipo 2 a escala nacional. El estudio GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness - Estrategias para la reducción de la glucemia en la diabetes: una comparativa de la eficacia) comparará los efectos beneficiosos y riesgos a largo plazo de cuatro fármacos ampliamente utilizados en el tratamiento de la diabetes, en combinación con metformina, la medicación de primera línea más frecuente para tratar la diabetes tipo 2. El estudio GRADE está buscando voluntarios latinos.
Para ver el Multimedia News Release, vaya a http://www.multivu.com/mnr/65066-nih-grade-study-on-type-2-diabetes-medication-seeks-latino-volunteers
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
Millennium Health, a leading health solutions company, today announced the launch of the Drop Them Off campaign, in partnership with the Mark Wahlberg Youth Foundation and the Partnership for Drug-Free Kids’ Medicine Abuse Project. Designed to increase awareness of the problem of youth misuse and abuse of prescription medicine, the campaign intends to educate parents and youth on how to properly use, store, and dispose of prescription medications by dropping them off at appropriate collection sites among other methods, to reduce access and opportunity for misuse or abuse. Educational content will be available online (www.DropThemOff.com) and through curriculum delivered through the Mark Wahlberg Youth Foundation’s community-based partners. Millennium Health is a Silver Sponsor of the Medicine Abuse Project, a campaign that aims to prevent half a million teens from abusing medicine by 2017.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7071752-millennium-health-drop-them-off/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
